Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2050-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood samples and health information (e.g., age at diagnosis, test results) are collected for the purposes of genetic research. The blood samples are assigned a number and stored in a repository for safe keeping until they are needed for a research project. Participants are persons who are healthy (not having high blood pressure, diabetes, or high cholesterol levels) or persons who have Diabetes Mellitus Type II(T2D) and live in Indiana. Participants complete a questionnaire at the time the blood sample is drawn. Visits are repeated at 2 and 5 years after initial contact. Researchers apply to the Fairbanks Institute for use of the blood samples and health information minus participant names and contact information. Their research is required to be related to find genes or substances made by genes that may be involved in Diabetes Mellitus Type II with the purpose of improving the investigators understanding of the illness potentially leading to the development of new diagnostic tools for identifying the illness, new treatments,or preventative measures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Aim:

The purpose of this study is to create an extensively annotated bio-repository platform for hypothesis-driven research that will lead to advancements in the diagnosis, treatment and prevention of diseases common to the population of Indiana. The second phase of this research platform will be created by collecting blood samples from two groups of individuals in the Central Indiana community, one with documented evidence of Diabetes Mellitus Type II(T2D), and a second group of age, gender and ethnicity matched individuals without clinical evidence of Diabetes. Each individual's blood sample will be linked to their clinical, demographic and epidemiological information, gathered both retrospectively and prospectively.

Recruitment:

This study will include 500 individuals with T2D (the T2D Group) and 500 individuals who are age, gender, and ethnicity matched to the T2D Group, but without presentation of clinical evidence of T2D (the Control Group). To reflect the growing representation of Hispanics in Central Indiana, Hispanics will be overly recruited in both groups so that the study population accurately reflects the general population of Central Indiana.

Follow-up:

As this is a prospective, longitudinal study, follow-up of study subjects is intended to include two follow up visit and continue indefinitely, unless, of course, at any time, consent for further follow-up is withdrawn by the subject. Follow-up will include visits at 2 and 5 years post initial contact and continuing access to the subject's medical record to pursue data concerning changes in the subject's health. Subjects may be contacted by telephone, mail or email every twelve months to ask if they wish to continue participation in the study. The 2 and 5 year follow up visits mirror the initial visit.

The collected dataset (made up of the collected blood samples linked to clinical and epidemiological information collected retrospectively and prospectively), will be used in medical research to find genes, or gene products such as RNA or proteins that will help in understanding the causes of disease and will guide the development of new treatments

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Type II

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Diabetes Controls Biospecimen

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

People with Diabetes Mellitus Type II

500 subjects will have T2D

No interventions assigned to this group

Healthy

500 persons who do not have T2D, hypertension or hypercholesterol

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Study subjects will be recruited for the T2D group based on a history confirmed by the medical record of at least one of the following:

* A fasting blood glucose of greater than or equal to 126 mg/dL on two separate occasions
* A random (non-fasting) blood glucose of greater than or equal to 200 mg/dL on two separate occasions
* A blood glucose of greater than 200 mg/dL at 2 hours during a standard oral glucose tolerance test
* A HgbA1c of greater than or equal to 6.5%

Females who are pregnant will be excluded.

Control Group

Study subjects for the Control Group will have:

* no confirmed history of T2D as defined above
* A fasting blood glucose of 100 mg/dL or less

\-

Exclusion Criteria

* Hepatitis B
* Hepatitis C
* AIDS (HIV positive)
* Tuberculosis
* Cancer (including melanoma, but excluding low-malignancy skin cancer)
* Non-autologous bone marrow transplant
* Blood transfusion within 120 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fairbanks Institute for Healthy Communities

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anantha Shekhar, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University School of Medine/CTSI

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FIHC-2009-01

Identifier Type: -

Identifier Source: org_study_id

Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

People with Diabetes Mellitus Type II

Healthy

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Indiana University School of Medicine

Richard M. Fairbanks Foundation

BioCrossroads

Regenstrief Institute, Inc.

Fairbanks Institute

Responsible Party

Principal Investigators

Anantha Shekhar, MD

Locations

American Health Network

Investigator's Research Group

American Health Network

American Health Network

American Health Network

Krannert Cardiology

Oral Health Research Institute

IU School of Medicine/CTSI

Alivio Medical Center

IU Medical Group

American Health Network

Countries

Related Links

Other Identifiers

FIHC-2009-01